Healthcare & pharmaceutical equity investment research

Healthcare Insights

Market cap

Date (published)

thematic

Healthcare

26.01.23

Machine learning in drug development

thematic

Healthcare

13.06.23

ASCO 2023 key takeaways

Healthcare

thematic

04.01.24

Outlook for 2024: Life sciences – where has the conviction gone?

Latest

Healthcare | Flash note

04.10.24

Immix Biopharma — US CAR-T trial progresses to dose expansion

Healthcare | Flash note

03.10.24

IRLAB Therapeutics — IRL757 starts strong in Phase I

Healthcare | Update

02.10.24

Cereno Scientific — CS1 shines in Phase IIa PAH trial

Healthcare | Flash note

02.10.24

Oryzon Genomics — FDA aligns on Phase III BPD plans

insight

Healthcare

28.11.23

Incannex’s US redomicile is now complete – what’s next?

insight

Healthcare

20.11.23

Newron Pharmaceuticals: EKF 2023 QuickView

insight

Healthcare

08.09.23

VolitionRx – On the cusp of a breakthrough in testing for sepsis

insight

Healthcare

20.07.23

Incannex Healthcare: Is life better on Nasdaq?

insight

Healthcare

25.05.23

An update on OpGen: Deals, expansion and revenues

insight

Healthcare

18.05.23

Volition: Views from the sharp end

Equities

Region

Market cap

Actinogen Medical (ACW)

Latest price

AUD0.03

— 0.00 (−3.85)

As at 04/10/2024

Market capitalisation: AUD77m

View equity

Flash note

Healthcare

27.08.24

Actinogen Medical — Further positive XanaCIDD results on depression

Update

Healthcare

22.08.24

Actinogen Medical — XanaCIDD data narrow the focus in depression

Flash note

Healthcare

28.06.24

Actinogen Medical — Publication of XanADu biomarker analysis

See more
content on

Actinogen Medical

AFT Pharmaceuticals (AFT)

Latest price

NZD3.12

▾ 0.01 (0.32)

As at 04/10/2024

Market capitalisation: NZD327m

View equity

Flash note

Healthcare

30.09.24

AFT Pharmaceuticals — Maxigesic IV reaches the Chinese shores

Flash note

Healthcare

09.08.24

AFT Pharmaceuticals — Hikma partnership expands to include Combogesic

Flash note

Healthcare

10.07.24

AFT Pharmaceuticals — Continued execution of footprint expansion

See more
content on

AFT Pharmaceuticals

Argent Biopharma (RGT)

Latest price

GBP0.27

▾ −0.50 (−1.82)

As at 04/10/2024

Market capitalisation: GBP14m

View equity

QuickView

Healthcare

05.09.24

Argent Biopharma — An innovative approach to drug development

Update

Healthcare

04.11.19

MGC Pharmaceuticals — Rapid prescription growth in Australia and the UK

Update

Healthcare

10.07.19

MGC Pharmaceuticals — Initial CannEpil purchase orders received

See more
content on

Argent Biopharma

Basilea Pharmaceutica (BSLN)

Latest price

CHF44.95

▾ −0.20 (−0.44)

As at 04/10/2024

Market capitalisation: CHF595m

View equity

Update

Healthcare

24.09.24

Basilea Pharmaceutica — BARDA backs Basilea’s anti-infectives programme

Flash note

Healthcare

09.09.24

Basilea Pharmaceutica — H2 rewards continue: US$25m Cresemba milestone

Flash note

Healthcare

28.08.24

Basilea Pharmaceutica — EU paediatric approval triggers CHF10m milestone

See more
content on

Basilea Pharmaceutica

Cantargia (CANTA)

Latest price

SEK2.93

▾ −0.15 (−4.87)

As at 04/10/2024

Market capitalisation: SEK566m

View equity

Flash note

Healthcare

19.04.23

Cantargia — Encouraging data for nadunolimab in CANFOUR

Flash note

Healthcare

14.03.23

Cantargia — First patient treated in Phase II part of TRIFOUR

Update

Healthcare

27.02.23

Cantargia — Next phase of clinical development in sight

See more
content on

Cantargia

Cereno Scientific (CRNO-B)

Latest price

SEK7.17

▾ 0.02 (0.28)

As at 04/10/2024

Market capitalisation: SEK2,008m

View equity

Update

Healthcare

02.10.24

Cereno Scientific — CS1 shines in Phase IIa PAH trial

Flash note

Healthcare

04.09.24

Cereno Scientific — CS1 granted OMPD, complementing FDA ODD

Update

Healthcare

02.09.24

Cereno Scientific — Pressing clinical assets forward to key inflection

See more
content on

Cereno Scientific

Chosa (CHOSA)

Latest price

SEK0.98

▾ −0.01 (−1.01)

As at 04/10/2024

Market capitalisation: SEK70m

View equity

Update

Healthcare

02.06.23

Chosa Oncology — Making headway in precision oncology

Update

Healthcare

28.02.22

RhoVac — On the home straight

Outlook

Healthcare

14.10.21

RhoVac — Phase IIb BRaVac study results in H122

See more
content on

Chosa

Creo Medical (CREO)

Latest price

GBP0.22

▾ 1.35 (6.40)

As at 04/10/2024

Market capitalisation: GBP77m

View equity

Flash note

Healthcare

19.09.24

Creo Medical — Consumables business divested in strategic move

Flash note

Healthcare

05.07.24

Creo Medical — Intuitive deal expansion is a notable milestone

Update

Healthcare

20.05.24

Creo Medical — Setting the stage for pivotal growth

See more
content on

Creo Medical

Immix Biopharma (IMMX)

Latest price

USD1.34

▾ −0.12 (−8.22)

As at 04/10/2024

Market capitalisation: USD41m

View equity

Flash note

Healthcare

04.10.24

Immix Biopharma — US CAR-T trial progresses to dose expansion

Update

Healthcare

14.08.24

Immix Biopharma — Full steam ahead with US CAR-T trial

Flash note

Healthcare

29.07.24

Immix Biopharma — US$8m grant to advance novel CAR-T treatment

See more
content on

Immix Biopharma

IRLAB Therapeutics (IRLAB-A)

Latest price

SEK12.95

▾ −0.15 (−1.15)

As at 04/10/2024

Market capitalisation: SEK679m

View equity

Flash note

Healthcare

03.10.24

IRLAB Therapeutics — IRL757 starts strong in Phase I

Flash note

Healthcare

01.10.24

IRLAB Therapeutics — Pirepemat Phase IIb trial completes enrolment

Flash note

Healthcare

05.09.24

IRLAB Therapeutics — New mesdopetam patent strengthens IP portfolio

See more
content on

IRLAB Therapeutics

Medigene (MDG1)

Latest price

EUR2.12

▾ −0.08 (−3.42)

As at 04/10/2024

Market capitalisation: EUR33m

View equity

Mendus (IMMU)

Latest price

SEK7.90

▾ −0.10 (−1.25)

As at 04/10/2024

Market capitalisation: SEK403m

View equity

Update

Healthcare

27.08.24

Mendus — Broad progress across the pipeline

Flash note

Healthcare

24.07.24

Mendus — Collaboration unveils path forward for ilixadencel

Flash note

Healthcare

21.06.24

Mendus — Recent clinical data highlight vididencel’s potential

See more
content on

Mendus

MindMed (MNMD)

Latest price

USD5.47

▾ −0.09 (−1.53)

As at 04/10/2024

Market capitalisation: USD447m

View equity

Newron Pharmaceuticals (NWRN)

Latest price

CHF7.90

▾ 0.03 (0.38)

As at 04/10/2024

Market capitalisation: CHF150m

View equity

Update

Healthcare

23.09.24

Newron Pharmaceuticals — Moving full steam towards pivotal studies

Flash note

Healthcare

26.06.24

Newron Pharmaceuticals — Evenamide road to registration and beyond

Flash note

Healthcare

14.05.24

Newron Pharmaceuticals — Evenamide potential for treatment of schizophrenia

See more
content on

Newron Pharmaceuticals

Nicox (ALCOX)

Latest price

EUR0.27

▾ −0.01 (−3.60)

As at 04/10/2024

Market capitalisation: EUR18m

View equity

Flash note

Investment Companies

22.03.24

Henderson EuroTrust — Proposed merger with Henderson European Focus Trust

Flash note

Healthcare

18.12.23

Nicox — Animal data show favourable profile vs Lumigan

Update

Investment Companies

13.12.23

Henderson EuroTrust — Good stock selection outweighing headwinds

See more
content on

Nicox

OpGen (OPGN)

Latest price

USD1.86

▾ 0.07 (3.91)

As at 04/10/2024

Market capitalisation: USD15m

View equity

Update

Healthcare

14.08.23

OpGen — Cash concerns dampen active Q2

Flash note

Healthcare

04.08.23

OpGen — FIND collaboration advances to development

Flash note

Healthcare

21.07.23

OpGen — Feasibility milestone from FIND collaboration

See more
content on

OpGen

Curated by Edison

singularityhub.com

The Next Step for AI in Biology Is to Predict How Proteins Behave in the Body

Healthcare

A new protein atlas can help turn static AI predictions of protein shapes into more fluid predictions of how proteins behave in the body.

Read article

www.genome.gov

The Cost of Sequencing a Human Genome

Healthcare

Estimated cost of sequencing the human genome over time since the Human Genome Project.

Read article

www.prnewswire.com

J.P. Morgan Launches New Life Sciences Private Capital Team Targeting Investments in Innovative Healthcare Companies

Healthcare

/PRNewswire/ -- J.P. Morgan Asset Management today announced the launch of a new life sciences private equity team, Life Sciences Private Capital. The new team...

Read article

insights.omnia-health.com

Leveraging nanotechnology to transform the disinfection industry

Healthcare

Co-founders of Kismet Technologies, Christina Drake and Shari Costantini, discuss how NanoRad, one of their flagship products, uses targeted application to kill a wide range of bacteria and viruses.

Read article

www.bain.com

2022 Healthcare Provider IT Report: Post-Pandemic Investment Priorities

Healthcare

As healthcare providers enter a new period of disruption, their software investment priorities present opportunities for vendors and investors.

Read article

Thematics

thematic

Healthcare

04.01.24

Outlook for 2024: Life sciences – where has the conviction gone?

thematic

Healthcare

20.11.23

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

thematic

Healthcare

13.11.23

VolitionRx – Decoding the DNA of cancer

thematic

Healthcare

13.06.23

ASCO 2023 key takeaways

thematic

Healthcare

26.01.23

Machine learning in drug development

thematic

Healthcare

06.01.23

Outlook for 2023: Biotechs remain central to novel drug development

thematic

Healthcare

04.01.23

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

thematic

Healthcare

20.12.22

Cell and gene therapies

Equities

Equities by Sector

Sectors

Thematics

Latest

Banco Angolano de Investimentos (BAI) – Money-centre bank with lending optionality

The art of measurement – Challenges in metrology

Vietnam Holding – Vietnam in the global digital race

Audiovisual

Latest

Card Factory – executive interview

The London Tunnels – executive interview

Medigene – executive interview

About Edison

About Edison

Careers

Healthcare

VolitionRx

9.35%

Healthcare Insights

Machine learning in drug development

ASCO 2023 key takeaways

Outlook for 2024: Life sciences – where has the conviction gone?

Latest

Immix Biopharma — US CAR-T trial progresses to dose expansion

IRLAB Therapeutics — IRL757 starts strong in Phase I

Cereno Scientific — CS1 shines in Phase IIa PAH trial

Oryzon Genomics — FDA aligns on Phase III BPD plans

Incannex’s US redomicile is now complete – what’s next?

Newron Pharmaceuticals: EKF 2023 QuickView

VolitionRx – On the cusp of a breakthrough in testing for sepsis

Incannex Healthcare: Is life better on Nasdaq?

An update on OpGen: Deals, expansion and revenues

Volition: Views from the sharp end

Equities

Actinogen Medical (ACW)

AUD0.03

Actinogen Medical — Further positive XanaCIDD results on depression

Actinogen Medical — XanaCIDD data narrow the focus in depression

Actinogen Medical — Publication of XanADu biomarker analysis

See morecontent on

AFT Pharmaceuticals (AFT)

NZD3.12

AFT Pharmaceuticals — Maxigesic IV reaches the Chinese shores

AFT Pharmaceuticals — Hikma partnership expands to include Combogesic

AFT Pharmaceuticals — Continued execution of footprint expansion

See morecontent on

Argent Biopharma (RGT)

GBP0.27

Argent Biopharma — An innovative approach to drug development

MGC Pharmaceuticals — Rapid prescription growth in Australia and the UK

MGC Pharmaceuticals — Initial CannEpil purchase orders received

See morecontent on

Basilea Pharmaceutica (BSLN)

CHF44.95

Basilea Pharmaceutica — BARDA backs Basilea’s anti-infectives programme

Basilea Pharmaceutica — H2 rewards continue: US$25m Cresemba milestone

Basilea Pharmaceutica — EU paediatric approval triggers CHF10m milestone

See morecontent on

Cantargia (CANTA)

SEK2.93

Cantargia — Encouraging data for nadunolimab in CANFOUR

Cantargia — First patient treated in Phase II part of TRIFOUR

Cantargia — Next phase of clinical development in sight

See morecontent on

Cereno Scientific (CRNO-B)

SEK7.17

Cereno Scientific — CS1 shines in Phase IIa PAH trial

Cereno Scientific — CS1 granted OMPD, complementing FDA ODD

Cereno Scientific — Pressing clinical assets forward to key inflection

See morecontent on

Chosa (CHOSA)

SEK0.98

Chosa Oncology — Making headway in precision oncology

RhoVac — On the home straight

RhoVac — Phase IIb BRaVac study results in H122

See morecontent on

Creo Medical (CREO)

GBP0.22

Creo Medical — Consumables business divested in strategic move

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on